For your patients with migraine,

Dosing & administration for migraine

Discover how eligible patients can get Emgality for as little as $0 for up to 12 months.* View savings cards.

*Terms and Conditions:
Offer good for up to 12 months of Emgality from Patient qualification into the program. Patients that have commercial drug insurance coverage for Emgality may be able to pay as little as $0 for a 30-day supply of Emgality. Offer subject to a monthly cap of wholesale acquisition cost plus usual and customary pharmacy charges and a separate annual cap of $4,900. Patients that have commercial drug insurance but do not have coverage for Emgality may be able to pay as little as $0 for their first fill of a 30-day supply of Emgality. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for Patients without commercial drug insurance or whose prescription claims for Emgality are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any State Patient or Pharmaceutical Assistance Program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found at

TRICARE® is a registered trademark of the Department of Defense (DoD), DHA.


  1. Ailani J, Burch RC, Robbins MS; the Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;00:1-19.
  2. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52:930-945.
  3. Data on File. Lilly USA, LLC. DOF-GZ-US-0060.
  4. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
  5. Aimovig [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; 2019.
  6. Ajovy [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019.
  7. Emgality [Autoinjector Instructions for Use]. Indianapolis, IN: Lilly USA, LLC.


Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.



Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache